Table 2.

Reproducibility data generated at the six study sites (phase II) during AST of 20 strains of M. tuberculosis

DrugStrain categorya (no. of strains)Test systemInhibitory concn (μg/ml)No. of cultures at site:Total no. of cultures
123456
CapreomycinS (14)BACTEC 460≤1.251413141171372
2.501027010
50001012
Middlebrook 7H10≤10.0131312c14141278
R (6)BACTEC 460>5.066666636
Middlebrook 7H10>10.066160c625
CycloserineS (20)BACTEC 460≤752020181714b89
10000135— 9
20000101— 2
Middlebrook 7H10≤301920181816— 91
EthionamideS (10)BACTEC 460≤0.62566633529
1.2534466528
2.51001103
Middlebrook 7H10≤5.079101010955
R (10)BACTEC 460≤0.6250000101
1.251211106
2.522122110
>2.576876943
Middlebrook 7H10≥5.01092c104c237
KanamycinS (11)BACTEC 460≤1.2587767843
2.534454323
Middlebrook 7H10≤5.011111111111065
R (9)BACTEC 460≤1.250010131
2.51101003
588888848
Middlebrook 7H10≥5.099997952
AmikacinS (12)BACTEC 460≤0.5121211c12121271
Middlebrook 7H10≤2.011111110121267
4.00001001
>4.01111004
R (8)BACTEC 460>2.088888848
Middlebrook 7H10>4.088887c847
ClofazimineS (19)BACTEC 460≤0.125131918191819106
0.256010108
Middlebrook 7H10≤0.5191918c1918c17110
10000022
R (1)BACTEC 460≤0.1250001001
0.50110103
>0.51000012
Middlebrook 7H10≤0.50011103
1.01100002
>1.00000011
OfloxacinS (19)BACTEC 460≤1.016151416181594
2.034531420
Middlebrook 7H10≤1.0181917c1418c1298
2.010150714
R (1)BACTEC 4604.01000001
>4.00111115
Middlebrook 7H10>4.01111116
RifabutinS (7)BACTEC 460≤0.566677739
1.01110003
Middlebrook 7H10≤0.577777742
R (13)BACTEC 4601.01100114
2.00011002
>2.012121212121272
Middlebrook 7H10≤0.51100114
1.00001203
2.00030205
>2.012129c125c1262
  • a S, susceptible; R, resistant.

  • b Site 6 was excluded (see Results).

  • c Results of some susceptibility tests are missing.